Effect of co-administration of varenicline and antidepressants on extracellular monoamine concentrations in rat prefrontal cortex.
Since a substantial proportion of smokers have comorbid mood disorders, the smoking cessation aid varenicline might occasionally be prescribed to patients who are simultaneously treated with antidepressants. Given that varenicline is a selective nicotinic acetylcholine receptor partial agonist and not a substrate or inhibitor of drug metabolizing enzymes, pharmacokinetic interactions with various classes of antidepressants are highly unlikely. It is, however, conceivable that varenicline may have a pharmacodynamic effect on antidepressant-evoked increases in central monoamine release. Interactions resulting in excessive transmitter release could cause adverse events such as serotonin syndrome, while attenuation of monoamine release could impact the clinical efficacy of antidepressants. To investigate this we examined whether varenicline administration modulates the effects of the selective serotonin reuptake inhibitor sertraline and the monoamine oxidase inhibitor clorgyline, given alone and combined, on extracellular concentrations of the monoamines serotonin, dopamine, and norepinephrine in rat brain by microdialysis. Given the important role attributed to cortical monoamine release in serotonin syndrome as well as antidepressant activity, the effects on extracellular monoamine concentrations were measured in the medial prefrontal cortex. Responses to maximally effective doses of sertraline or clorgyline and of sertraline plus clorgyline were the same in the absence as in the presence of a relatively high dose of varenicline, which by itself had no significant effect on cortical monoamine release. This is consistent with the binding profile of varenicline that has insufficient affinity for receptors, enzymes, or transporters to inhibit or potentiate the pharmacologic effects of antidepressants. Since varenicline neither diminished nor potentiated sertraline- or clorgyline-induced increases in neurotransmitter levels, combining varenicline with serotonergic antidepressants is unlikely to cause excessive serotonin release or to attenuate antidepressant efficacy via effects on cortical serotonin, dopamine or norepinephrine release.
Department of Neuroscience, Pfizer Global Research and Development, Groton, CT 06340, USA. hans.rollema@pfizer.com
Hans
H
Rollema
Gary G
GG
Wilson
Theodore C
TC
Lee
Joost H A
JH
Folgering
Gunnar
G
Flik
D000818:Animals; D000928:Antidepressive Agents / Q000494:pharmacology*; D001552:Benzazepines / Q000494:pharmacology*; D015306:Biogenic Monoamines / Q000378:metabolism*; D002851:Chromatography, High Pressure Liquid; D003010:Clorgyline / Q000494:pharmacology; D003627:Data Interpretation, Statistical; D004298:Dopamine / Q000378:metabolism; D004347:Drug Interactions; D005110:Extracellular Space / Q000187:drug effects / Q000378:metabolism*; D008297:Male; D017551:Microdialysis; D008996:Monoamine Oxidase Inhibitors / Q000494:pharmacology; D018377:Neurotransmitter Agents / Q000378:metabolism; D018722:Nicotinic Agonists / Q000494:pharmacology*; D009638:Norepinephrine / Q000378:metabolism; D017397:Prefrontal Cortex / Q000187:drug effects / Q000378:metabolism*; D011810:Quinoxalines / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar; D012701:Serotonin / Q000378:metabolism; D020280:Sertraline / Q000494:pharmacology; D000068580:Varenicline; D050493:Vesicular Monoamine Transport Proteins / Q000378:metabolism
D000928:Antidepressive Agents; D001552:Benzazepines; D015306:Biogenic Monoamines; D008996:Monoamine Oxidase Inhibitors; D018377:Neurotransmitter Agents; D018722:Nicotinic Agonists; D011810:Quinoxalines; D050493:Vesicular Monoamine Transport Proteins; D012701:Serotonin; D003010:Clorgyline; D020280:Sertraline; D004298:Dopamine; D000068580:Varenicline; D009638:Norepinephrine